Zhifei Biological Plans IPO Of 40 Million Shares For Expansion Projects
This article was originally published in PharmAsia News
Zhifei Biological plans an initial public offering with no more than 40 million shares of common stock in the A share market
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.